Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project.


Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 23 9 2018
medline: 2 6 2020
entrez: 23 9 2018
Statut: ppublish

Résumé

In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glu cose Contro l at H ome for People with Chronic Disea se) is aiming to develop integrated AP solutions (APplus) tailored to the needs of people with type 2 diabetes (T2D). APplus comprises a product and service package complementing the AP system by obligatory training as well as home visits and telemedical consultations on demand. Outcome predictors and performance indicators shall help to identify people who could benefit most from AP usage and facilitate the measurement of AP impact in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences, and enhancing AP functionalities and interconnectedness. By being part of the European Institute of Innovation and Technology (EIT) Health public-private partnership, CLOSE is committed to the EIT "knowledge triangle" pursuing the integrated advancement of technology, education, and business creation. Putting stakeholders, education, and impact into the center of APplus advancement is considered key for achieving wide AP use in T2D care.

Identifiants

pubmed: 30241444
doi: 10.1177/1932296818803588
pmc: PMC6399797
doi:

Substances chimiques

Biomarkers 0
Blood Glucose 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

261-267

Commentaires et corrections

Type : CommentIn

Références

Diabetes Care. 2012 Dec;35(12):2650-64
pubmed: 23100048
J Diabetes Sci Technol. 2018 Sep;12(5):1029-1040
pubmed: 29681172
Stud Health Technol Inform. 2004;107(Pt 2):1343-7
pubmed: 15361033
Diabetes Care. 2014;37(5):1198-203
pubmed: 24026542
Int J Technol Assess Health Care. 2015;31(6):399-406
pubmed: 26868190
Diabetes Care. 2015 Jan;38(1):140-9
pubmed: 25538310
Lancet Diabetes Endocrinol. 2017 Feb;5(2):117-124
pubmed: 27836235
Diabet Med. 2018 Apr;35(4):436-449
pubmed: 29247547
J Diabetes Sci Technol. 2016 May 03;10(3):772-81
pubmed: 26645793
Milbank Q. 2015 Jun;93(2):263-300
pubmed: 26044630
J Diabetes Sci Technol. 2018 Nov;12(6):1223-1226
pubmed: 30079769
Eur J Public Health. 2004 Mar;14(1):3-9
pubmed: 15080382
Lancet Diabetes Endocrinol. 2015 Dec;3(12):939-47
pubmed: 26432775
N Engl J Med. 2018 Aug 09;379(6):547-556
pubmed: 29940126
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
BMJ Open Diabetes Res Care. 2018 Aug 12;6(1):e000527
pubmed: 30116541
Prev Chronic Dis. 2012;9:E100
pubmed: 22595321
Lancet. 2014 Oct 4;384(9950):1265-72
pubmed: 24998009
Ann N Y Acad Sci. 2014 Apr;1311:102-23
pubmed: 24725149
BMJ. 2018 Apr 18;361:k1310
pubmed: 29669716
Exp Clin Endocrinol Diabetes. 2015 May;123(5):299-302
pubmed: 25658664
J Diabetes Complications. 2016 Nov - Dec;30(8):1548-1554
pubmed: 27524280
Ann Fam Med. 2013 Jul-Aug;11(4):363-70
pubmed: 23835823
Diabetes Res Clin Pract. 2012 Oct;98(1):5-10
pubmed: 22917639
J Diabetes Sci Technol. 2016 Jun 28;10(4):950-8
pubmed: 26888971
Nutrients. 2017 Apr 28;9(5):
pubmed: 28452927
Lancet Diabetes Endocrinol. 2013 Sep;1(1):28-34
pubmed: 24622264
Arch Public Health. 2014 Feb 27;72(1):6
pubmed: 24576356
Diabetes Metab. 2010 Feb;36(1):79-85
pubmed: 20074990
J Diabetes Sci Technol. 2015 Jul;9(4):792-800
pubmed: 25852075
Ann Intern Med. 2017 Sep 19;167(6):365-374
pubmed: 28828487
N Engl J Med. 2015 Nov 26;373(22):2129-2140
pubmed: 26379095
Diabetes Care. 2015 Jun;38(6):1036-43
pubmed: 25998296

Auteurs

Freimut Schliess (F)

1 Profil, Neuss, Germany.

Tim Heise (T)

1 Profil, Neuss, Germany.

Beata Mianowska (B)

2 Department of Pediatrics, Oncology, Hematology and Diabetology Łódź, Medical University of Łódź, Poland.

Constance Stegbauer (C)

3 aQua-Institute for Applied Quality Improvement and Research in Health Care, Goettingen, Germany.

Björn Broge (B)

3 aQua-Institute for Applied Quality Improvement and Research in Health Care, Goettingen, Germany.

Pieter Gillard (P)

4 Clinical and Experimental Endocrinology, Catholic University of Leuven, Leuven, Belgium.

George Binkley (G)

5 IESE Business School, University of Navarra, Barcelona, Spain.

Véronique Crône (V)

6 Air Liquide Santé International, Gentilly, France.

Sébastien Carlier (S)

6 Air Liquide Santé International, Gentilly, France.

Cécile Delval (C)

6 Air Liquide Santé International, Gentilly, France.

Anton Petkov (A)

7 Sanofi, Frankfurt/Main, Germany.

Jan-Philipp Beck (JP)

8 EIT Health, Munich, Germany.

Volker Lodwig (V)

9 EIT Health Germany, Mannheim/Heidelberg, Germany.

Mikolaj Gurdala (M)

10 EIT Health InnoStars, Budapest, Hungary.

Joachim Szecsenyi (J)

3 aQua-Institute for Applied Quality Improvement and Research in Health Care, Goettingen, Germany.

Magda Rosenmöller (M)

5 IESE Business School, University of Navarra, Barcelona, Spain.

Katarzyna Cypryk (K)

11 Department of Internal Medicine and Diabetology, Medical University of Łódź, Łódź, Poland.

Chantal Mathieu (C)

4 Clinical and Experimental Endocrinology, Catholic University of Leuven, Leuven, Belgium.

Eric Renard (E)

12 Montpellier University Hospital, Department of Endocrinology, Diabetes, Nutrition, and Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH